Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have no idea but I am still all in because my sell order did not get filled at .25 yesterday or was it the day before.
It may be a omen. I for surely could use that kind of boost after this week. Double ouch.
Harley: mine has a major blackeye. It will take more than a steak to make it better.
ACLS was about the only thing bucking the trend.
I'm tyring to sell at .25. Only go a partial fill earlier.
It just hit it's low for the day. 1.49
Funny you should ask. I'm in XTXI but thinking about exchanging it for Citi.
SIRI News:
Liberty to loan Sirius $530 mln, get 40 pct stake 02/17 08:28 AM
NEW YORK, Feb 17 (Reuters) - Liberty Media <LINTA.O> has agreed to $530 million in loans to Sirius XM Radio Inc (SIRI:$0.1049,$0.0309,41.76%) , saving the satellite radio provider from possible bankruptcy and giving Liberty a 40 percent equity stake.
Under the agreement, Liberty, controlled by media mogul John Malone, would offer loans to Sirius, a portion of which will help pay $171.6 million in debt that was due on Tuesday.
Had Sirius been unable to make that payment it said it would have had to seek bankruptcy protection.
Once the loans are completed, Sirius XM will issue Liberty 12.5 million shares of preferred stock convertible into 40 percent of the common stock of Sirius XM.
Liberty expects that Malone and Greg Maffei will join the Sirius XM Board of Directors. (Reporting by Franklin Paul, editing by Dave Zimmerman)
Anybody watching SIRI? Huge PM volume. .24.
Yes, I did. Thank you. How was yours?
Good Morning.
And that does not include all the back pay they get for unsued vacation time which is uncapped for many gov't employees of rank.
I guess they didn't look at what taxpayers foot in NJ yet.
School principles in NJ get 70K+ upon retirement for the rest of their lives. Superintendents get 6 figures.
No, Ventana Medical Systems in Oro Valley.
Rev,
I worked for Ventana.
Rev, I'm very familiar with Tucson. i worked for the largest employer in Tucson. I've been there many times. My favorite restaurant is Wildflower. Love the winter months there. Perfect weather. Summers a little crispy.
Good Morning, Happy Valentines Day!
Chart: nice call on ASIA. The one time I don't play one of your calls BOOM.
Good Morning.
Inxy according to what I learned there are some reporting issues.
RT: I did but only with 5K shares. I now have 15K average of .19.
Sheff, SRZ I'm not sure what's going on with this stock .77 now. No news anywhere.
Good Morning WU.
Richboy, SIRI News:
Sirius XM Radio (SIRI:$0.1139,$0.0039,3.55%) has hired advisers to prepare for a possible bankruptcy filing, according to sources. It is unclear how bankruptcy would affect customers and service is unlikely to be interrupted but the company may have to terminate high price tag contracts with stars such as Howard Stern and Martha Stewart. Documents and analysis are close to completion and a filing could come in a matter of days. [Reference Link]:[http://blogs.wsj.com/deals/2009/02/10/bank-of-america-memo-i-know-that-talk-can-be-cheap/]
If ACLS pays us off like PDGI, I have all the patience in the world.
I never thought SRZ would go down to .84. Wow. I could not find any news. I am thinking this may be dilution caused by their refi.
Ewwwww. Thanks. H11 means regualtory concern. That's not good.
ACLS: Helping the cause also added 5K at ask.
Me. I'm having fun.
Good Morning Everyone. CTIC News:
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone 02/10 01:30 AM
SEATTLE, Feb. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTIC:$0.0821,$0.0021,2.62%) (CTI) today announced that they have executed a definitive collaborative agreement with IDIS to manage its investigational drug pixantrone on a named patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with relapsing aggressive non-Hodgkin's lymphoma. This program is expected to be initiated by second quarter of 2009.
"Under the named patient program, CTI will be able to provide pixantrone to European patients in need at the prescriber's request while moving it through the approval process in the United States," noted Craig Philips, President of CTI. "With the announcement of preliminary results showing significantly higher rate of complete remission and improvement in progression-free survival for patients receiving pixantrone compared to standard chemotherapeutic agents, we expect to receive a number of requests for pixantrone to treat specific patients."
"Pixantrone is an important new treatment with impressive remission and progression-free survival data," said Dr. Raul Herbrecht of Strasbourg University Hospital in France. "This drug is also important because it meets an unmet medical need for this group of patients. I have been impressed by the good tolerance and efficacy of pixantrone since the first clinical trial we had with this drug in our department. We obtained excellent results in salvage therapy of non-Hodgkin's lymphoma in heavily pretreated patients and several years later some of our patients are still in complete response. These positive results have been confirmed in further studies," Dr Herbrecht added.
The EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.
"We are pleased to be working with Cell Therapeutics (CTIC:$0.0821,$0.0021,2.62%) to ensure that those patients with non-Hodgkin's Lymphoma who do not respond to current available therapies have access to pixantrone through a named patient program," said Natalie Douglas, CEO, IDIS. "CTI's potentially life-saving medicine can offer these patients renewed hope for remission. We are deeply committed to work in partnership with pharmaceutical and biotechnology companies to give physicians and their patients access to new and innovative medicines through regulated and responsible channels."
CTI announced in November 2008 that it had achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/CRu+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). In January, 2009 CTI announced preliminary results that show patients treated with pixantrone experienced a statistically significant improvement in median progression-free survival, compared with other single-agent chemotherapeutic agents (4.7 months vs. 2.6 months, hazard ratio = 0.6; p = 0.0074, pixantrone vs. standard chemotherapy) based on an intent to treat analysis. PFS, CR/CRu and ORR were determined by an independent assessment panel that was blinded to the treatment assignments.
The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised.
The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004 and pixantrone has received fast track designation for this indication.
About Pixantrone
Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.
About IDIS
IDIS is the world leader in the development and implementation of named patient programs and has a proven track record of working in strategic partnership with US-based companies to bring new drugs to Europe for the first time. IDIS supports customers in over 100 countries, supplying more than 400 different medicines per month and responding to more than half a million requests on a named patient basis to medical professionals worldwide. For more information on IDIS please visit our website at http://www.idispharma.com.
CTIC News:
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone 02/10 01:30 AM
SEATTLE, Feb. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTIC:$0.0821,$0.0021,2.62%) (CTI) today announced that they have executed a definitive collaborative agreement with IDIS to manage its investigational drug pixantrone on a named patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with relapsing aggressive non-Hodgkin's lymphoma. This program is expected to be initiated by second quarter of 2009.
"Under the named patient program, CTI will be able to provide pixantrone to European patients in need at the prescriber's request while moving it through the approval process in the United States," noted Craig Philips, President of CTI. "With the announcement of preliminary results showing significantly higher rate of complete remission and improvement in progression-free survival for patients receiving pixantrone compared to standard chemotherapeutic agents, we expect to receive a number of requests for pixantrone to treat specific patients."
"Pixantrone is an important new treatment with impressive remission and progression-free survival data," said Dr. Raul Herbrecht of Strasbourg University Hospital in France. "This drug is also important because it meets an unmet medical need for this group of patients. I have been impressed by the good tolerance and efficacy of pixantrone since the first clinical trial we had with this drug in our department. We obtained excellent results in salvage therapy of non-Hodgkin's lymphoma in heavily pretreated patients and several years later some of our patients are still in complete response. These positive results have been confirmed in further studies," Dr Herbrecht added.
The EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.
"We are pleased to be working with Cell Therapeutics (CTIC:$0.0821,$0.0021,2.62%) to ensure that those patients with non-Hodgkin's Lymphoma who do not respond to current available therapies have access to pixantrone through a named patient program," said Natalie Douglas, CEO, IDIS. "CTI's potentially life-saving medicine can offer these patients renewed hope for remission. We are deeply committed to work in partnership with pharmaceutical and biotechnology companies to give physicians and their patients access to new and innovative medicines through regulated and responsible channels."
CTI announced in November 2008 that it had achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/CRu+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). In January, 2009 CTI announced preliminary results that show patients treated with pixantrone experienced a statistically significant improvement in median progression-free survival, compared with other single-agent chemotherapeutic agents (4.7 months vs. 2.6 months, hazard ratio = 0.6; p = 0.0074, pixantrone vs. standard chemotherapy) based on an intent to treat analysis. PFS, CR/CRu and ORR were determined by an independent assessment panel that was blinded to the treatment assignments.
The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised.
The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004 and pixantrone has received fast track designation for this indication.
About Pixantrone
Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.
About IDIS
IDIS is the world leader in the development and implementation of named patient programs and has a proven track record of working in strategic partnership with US-based companies to bring new drugs to Europe for the first time. IDIS supports customers in over 100 countries, supplying more than 400 different medicines per month and responding to more than half a million requests on a named patient basis to medical professionals worldwide. For more information on IDIS please visit our website at http://www.idispharma.com.
It was based on the money I had left after selling a pennie stock that went the wrong way last year. I was patient enough. I think I will make it up the loss very nicely with ACLS. I loved PDGI so I think I could love ACLS.
I decided on ACLS. 2.5K.
If the Bro portfolio had spare change would you be adding this one ACLS? I'm buying for my SIS portfolio.
Joined you in ACLS at .33. From the DD sounds like it's a good take over candidate.
You beat me. BAC Weeeeeeeeee.
XTXI now at 3.52 moving nicely.
Thanks GF.
GF. Are you holding BAC? If so, what are your thoughts? Thanks
Good Afternoon Everyone.
Today was so much fun. Thanks Chart